Section
Pipeline
Late-stage drugs with significant commercial implications
PipelineEndpoints News ↗
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been app…
PipelinePharmaceutical Technology ↗
The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early b…
PipelineFierceBiotech ↗
A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But …
PipelineBriefing
The Volga phase 3 trial showed Imfinzi plus Padcev improved survival in muscle-invasive bladder cancer, positi…
PipelinePharmaceutical Technology ↗
During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in trea…
PipelineFierceBiotech ↗
Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.